Halkier-Sørensen L, Andresen J
Department of Dermatology, University of Aarhus, Denmark.
J Am Acad Dermatol. 1989 Jan;20(1):83-7. doi: 10.1016/s0190-9622(89)70012-8.
Ninety patients aged 17 to 80 years were treated with etretinate for disorders of keratinization and were studied for bone changes. The treatment lasted from 0.1 to 7.9 years, mean 2.4 years. The average dosage of etretinate was 0.57 mg/kg/day (range 0.21 to 1.32 mg/kg/day), and the total dose was 31 gm (range 1 to 197 gm). Standard radiographs of the axial and peripheral skeleton were evaluated. The films of 44 patients showed skeletal abnormalities such as periosteal thickening, hyperostosis of the vertebral column, disk degeneration, osteoporosis, calcification of the spinal ligaments, and slender long bones. The present data indicate that the risk of skeletal disorders in adults treated with etretinate is significant (44 of 90), but that the severity of changes is minor.
90名年龄在17至80岁之间的患者因角化异常接受了依曲替酯治疗，并对其骨骼变化进行了研究。治疗持续时间为0.1至7.9年，平均2.4年。依曲替酯的平均剂量为0.57毫克/千克/天（范围为0.21至1.32毫克/千克/天），总剂量为31克（范围为1至197克）。对轴向和外周骨骼的标准X光片进行了评估。44名患者的X光片显示出骨骼异常，如骨膜增厚、脊柱骨质增生、椎间盘退变、骨质疏松、脊柱韧带钙化以及长骨纤细。目前的数据表明，接受依曲替酯治疗的成年人出现骨骼疾病的风险很高（90例中有44例），但变化的严重程度较小。
